Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is well positioned in the life sciences tools and diagnostics industry, with a strong presence in both the protein sciences and diagnostic and genomics segments. The company's global operations and diverse product portfolio make it attractive to a wide range of customers and markets. Additionally, Bio-Techne's recent acquisition of Wilson Wolf is expected to further enhance its standing in the industry and contribute to future growth. The company's strong focus on sustainability and corporate governance also speaks to its commitment to long-term success. Overall, we believe Bio-Techne has solid fundamental reasons for continued growth and success in the future, making it an attractive investment opportunity.

Bears say

Bio-Techne is facing headwinds in the near-term due to challenges in the cell therapy market and a delay in demand pick-up, but the company has implemented self-help initiatives to improve its overall business. Additionally, the recent acquisition of Wilson Wolf, which gives Bio-Techne a strong presence in the growing cell therapy market, is a positive move for the company's long-term growth prospects. While Bio-Techne may be facing some competitive pressures in certain markets, the overall industry outlook remains strong, with continued investments from large pharmaceutical companies and positive signals from the biotech sector.

Bio-Techne (TECH) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 10 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.